NF
TEVA icon

Norwood Financial’s Teva Pharmaceuticals TEVA Stock Holding History

Norwood Financial’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-50
Closed -$510 – 285
2023
Q3 		$510 Hold
50
– – ﹤0.01% 283
2023
Q2 		$376 Hold
50
– – ﹤0.01% 285
2023
Q1 		$442 Hold
50
– – ﹤0.01% 280
2022
Q4 		$456 Hold
50
– – ﹤0.01% 278
2022
Q3 		$0 Hold
50
– – ﹤0.01% 279
2022
Q2 		$0 Hold
50
– – ﹤0.01% 266
2022
Q1 		$0 Hold
50
– – ﹤0.01% 270
2021
Q4 		$0 Buy
+50
New +$451 ﹤0.01% 270

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Norwood Financial's TEVA Position: Q4 2023 in Review

Norwood Financial sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 50 shares — an estimated $510 sold.

Norwood Financial first reported a position in TEVA in Q4 2021 and held it in 8 quarters. The position peaked at $510 in Q3 2023. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • Norwood Financial reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Norwood Financial sold 50 Teva Pharmaceuticals shares in Q4 2023, an estimated $510.
  • Norwood Financial first reported a position in Teva Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • Norwood Financial's Teva Pharmaceuticals position peaked at $510 in Q3 2023.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Norwood Financial's 13F filing for Q4 2023, filed 12 Jan 2024.